Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

NCT05684653 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Orelabrutinib Tablets

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.